Labcorp Q2 revenue slightly beats estimates, lifts 2026 outlook
Reuters2026/07/30 11:01
Overview
U.S. laboratory services provider's Q2 revenue up 5.8%, slightly beating analyst expectations
Adjusted EPS for Q2 rose 14.9% to $4.99
Company raised 2026 revenue growth and adjusted EPS guidance, boosted share buyback by $1.0 bln
Outlook
Labcorp raises 2026 enterprise revenue growth guidance to 5.4%-6.3%
Company expects 2026 adjusted EPS between $18.10 and $18.55
Result Drivers
ORGANIC GROWTH AND OPERATING EFFICIENCIES - Co said increases in adjusted operating income and margin were due to organic growth and operating efficiencies
ONCOLOGY AND SPECIALTY TESTING - Co cited expansion in oncology offerings and high-growth specialty areas as drivers of business momentum
ACQUISITIONS AND NEW TEST LAUNCHES - Co said acquisitions and launches of new diagnostic tests, including nationwide rollout of ColoSense and new genetic health panels, contributed to growth
Company press release: ID:nPnb5RLPXa
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q2 Revenue |
Slight Beat* |
$3.73 bln |
$3.71 bln (14 Analysts) |
Q2 Adj EPS from Cont Ops |
|
$4.99 |
|
Q2 EPS from Cont Ops |
|
$3.64 |
|
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities services peer group is "buy"
Wall Street's median 12-month price target for Labcorp Holdings Inc is $320.00, about 4.2% above its July 29 closing price of $307.15
The stock recently traded at 16 times the next 12-month earnings vs. a P/E of 15 three months ago
Reuters Recommended Reads
July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook
July 29 - GE Healthcare Q2 revenue rises 5.7% on Pharmaceutical Diagnostics unit strength
July 28 - IQVIA Q2 revenue beats estimates; outlook raised
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Hagerty prices upsized secondary offering of 9,250,000 Class A shares at $11.95 each
BKV prices upsized USD 500 million convertible senior notes offering
Centrus Energy prices offering with warrants for 6,992,382 shares
Rohartindo Nusantara Luas says unaware of any material information behind share volatility